StocktoriaEnsysce Biosciences, Inc. ENSC
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
0/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M |
| Operating income | -$10.2M | -$6.7M | -$10.7M | -$24.2M | -$19.9M |
| Operating cash flow | -$7.8M | -$7.5M | -$10.8M | -$17.9M | -$8.2M |
| Free cash flow | -$7.9M | — | — | — | — |
| Total assets | $7.5M | $5.6M | $2.7M | $5.9M | $16.4M |
| Total liabilities | $4.6M | $2.2M | $3.4M | $9.9M | $24.6M |
| Shareholders' equity | $2.9M | $3.4M | -$651,267 | -$4.0M | -$8.2M |
| Ratios | |||||
| Operating margin | -202.1% | -129.2% | -480.5% | -959.9% | -562.7% |
| FCF margin | -156.5% | — | — | — | — |
| Current ratio | 1.59 | 2.42 | 0.69 | 0.56 | 0.95 |
| Revenue growth | -2.8% | 133.6% | -11.6% | -28.5% | -10.2% |
Why these scores methodology →
Piotroski F-score: 0/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001716947 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.